Drugs Previously Listed on the Index to Drug-Specific Information
(http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm)

• Aprotinin (marketed as Trasylol)
• Dolophine (marketed as Methadone)
• Exenatide (marketed as Bayetta)
• Gadolinium
  • Gadobenate Dimeglumine (marketed as Multihance)
  • Gadodiamide (marketed as Omniscan)
  • Gadopentetate Dimeglumine (marketed as Magnivist)
  • Gadoteridol (marketed as Prohance)
  • Gadoversetamide (marketed as Optimark)
• Hydromorphone (marketed as Pallodone)
• Natalizumab (marketed as Tysabri)
• Natalizumab (marketed as Tysabri)
• Nimodipine (marketed as Nimotop)
• Omeprazole (marketed as Prilosec) Esomeprazole (marketed asNexium)
• Pergolide (marketed as Permax)
• Rosiglitazone (marketed as Avandia, Avandamet, and Avandaryl)
• Technetium (marketed as NeutroSpec)
• Triaminic Vaport Patch

Back to Top     Back to Drug Index

PDF requires the free Adobe Acrobat Reader

Date created: December 28, 2007, updated June 4, 2008

CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | Privacy | Accessibility | HHS Home Page

FDA/Center for Drug Evaluation and Research